Gapping down
In reaction to disappointing earnings/guidance: RGSE -17.9%, HLX -11.4%, WLT -10.1%, IHG -5.6%, VNR -5.1%, AGIO -3.8%, WWW -3.5%, GLF -2.6%, USTR -1.5%, CADC -1.5%, CRY -0.9%, EPE -0.8%, MGM -0.8%, SYKE -0.7%, PES -0.7%
Select silver/mining stocks trading lower: SSRI -3.3%, SLV -3.0%, PAAS -2.4%, SLW -2%
Other news: CLTX -82.3% (announces Phase II trial of MRX-6 cream 2% in pediatric Atopic Dermatitis did not reach primary endpoint), VBLT -44.7% (announces removal of FDA partial clinical hold on VB-111), WHX -21.7% (NYSE suspends trading, company expects trading to move to OTC effective with the opening of trading on February 17, 2015), JOEZ -12.4% (disclosed it received an additional notice of defaults and events of default), NBG -10.6% (no resolution in Greece/EU talks), MNST -2.5% (disclosed that in relation to its previously announced agreement with Coca-Cola (KO), it expects to incur costs associated with the transition of its distribution arrangements in an amount currently estimated to be $280 mln), QTWO -2.3% (files for offering of ~4.56 mln shares of common stock: co selling 1.5 mln shares, selling stockholders selling ~3.06 mln shares), ASML -2% (still checking), ARMH -1.8% (still checking), GSK -1.6% (still checking), AZN -1.5% (US District Court rules PULMICORT RESPULES patent is invalid), GGP -0.9% (disclosed that it has extended its employment agreement with CEO Sandeep Mathrani for an initial five year term)
Analyst comments: BID -4.3% (downgraded to Market Perform from Outperform at Cowen), CVC -1.7% (downgraded to Sell from Neutral at UBS), M -1.4% (initiated with an Underweight at Barclays), LYB -1.2% (downgraded to Neutral from Buy at Citigroup), JWN -1.1% (downgraded to Underweight at Barclays), ZAYO -1.1% (downgraded to Underperform from Neutral at Macquarie)
In reaction to disappointing earnings/guidance: RGSE -17.9%, HLX -11.4%, WLT -10.1%, IHG -5.6%, VNR -5.1%, AGIO -3.8%, WWW -3.5%, GLF -2.6%, USTR -1.5%, CADC -1.5%, CRY -0.9%, EPE -0.8%, MGM -0.8%, SYKE -0.7%, PES -0.7%
Select silver/mining stocks trading lower: SSRI -3.3%, SLV -3.0%, PAAS -2.4%, SLW -2%
Other news: CLTX -82.3% (announces Phase II trial of MRX-6 cream 2% in pediatric Atopic Dermatitis did not reach primary endpoint), VBLT -44.7% (announces removal of FDA partial clinical hold on VB-111), WHX -21.7% (NYSE suspends trading, company expects trading to move to OTC effective with the opening of trading on February 17, 2015), JOEZ -12.4% (disclosed it received an additional notice of defaults and events of default), NBG -10.6% (no resolution in Greece/EU talks), MNST -2.5% (disclosed that in relation to its previously announced agreement with Coca-Cola (KO), it expects to incur costs associated with the transition of its distribution arrangements in an amount currently estimated to be $280 mln), QTWO -2.3% (files for offering of ~4.56 mln shares of common stock: co selling 1.5 mln shares, selling stockholders selling ~3.06 mln shares), ASML -2% (still checking), ARMH -1.8% (still checking), GSK -1.6% (still checking), AZN -1.5% (US District Court rules PULMICORT RESPULES patent is invalid), GGP -0.9% (disclosed that it has extended its employment agreement with CEO Sandeep Mathrani for an initial five year term)
Analyst comments: BID -4.3% (downgraded to Market Perform from Outperform at Cowen), CVC -1.7% (downgraded to Sell from Neutral at UBS), M -1.4% (initiated with an Underweight at Barclays), LYB -1.2% (downgraded to Neutral from Buy at Citigroup), JWN -1.1% (downgraded to Underweight at Barclays), ZAYO -1.1% (downgraded to Underperform from Neutral at Macquarie)